This inventor holds 2 USPTO granted patents. Top assignees: North Carolina State University, The University of North Carolina at Chapel Hill, The Ohio State University. Active years: 2013-2015.
Company Filing History:
2 out of 1,486 
2 out of 1,322 
1 out of 1,572 
Years Active: 2013-2015
Title: Anka N Veleva: Innovator in Targeted Therapeutics
Introduction
Anka N Veleva is a prominent inventor based in Cary, NC (US), known for her significant contributions to the field of targeted therapeutics. With a total of 2 patents, her work focuses on innovative methods and compositions that enhance the delivery and detection of bioactive compounds in neovascular growth.
Latest Patents
Veleva's latest patents include groundbreaking methods and compositions for targeting sites of neovascular growth. One patent details compositions and methods for targeted delivery to and detection of tumor vasculature. These compositions consist of polypeptides conjugated to or complexed with a bioactive compound, which can bind to outgrowth endothelial cells (OEC) or their circulating progenitors. Additionally, methods for identifying other polypeptides with similar binding characteristics are provided. Another patent focuses on peptides specific for human blood outgrowth endothelial cells, offering compositions that include peptide ligands capable of binding OEC with high affinity and specificity. These innovations are crucial for isolating OEC and recruiting them to therapeutic sites.
Career Highlights
Anka N Veleva has worked at esteemed institutions such as the University of North Carolina at Chapel Hill and North Carolina State University. Her research has significantly advanced the understanding of neovascular growth and its implications in therapeutic applications.
Collaborations
Throughout her career, Veleva has collaborated with notable professionals, including Cam Patterson and Stuart L Cooper. These partnerships have further enriched her research and contributions to the field.
Conclusion
Anka N Veleva's innovative work in targeted therapeutics exemplifies her dedication to advancing medical science. Her patents and research continue to pave the way for new therapeutic strategies in treating neovascular growth.